{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:23:09Z","timestamp":1790997789289,"version":"4.1.0"},"reference-count":32,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2015,2,20]],"date-time":"2015-02-20T00:00:00Z","timestamp":1424390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Int J Toxicol"],"published-print":{"date-parts":[[2015,3]]},"abstract":"<jats:p>A 2-week study in rats identified target organs of oxfendazole toxicity to be bone marrow, epididymis, liver, spleen, testis, and thymus. Female rats had greater oxfendazole exposure and exhibited toxicities at lower doses than did males. Decreased white blood cell levels, a class effect of benzimidazole anthelmintics, returned to normal during the recovery period. The no observed adverse effect level was determined to be &gt;5 but &lt;25 mg\/kg\/d and the maximum tolerated dose 100 mg\/kg\/d. The highest dose, 200 mg\/kg\/d, resulted in significant toxicity and mortality, leading to euthanization of the main study animals in this group after 7 days. Oxfendazole did not exhibit genetic toxicology signals in standard Ames bacterial, mouse lymphoma, or rat micronucleus assays nor did it provoke safety concerns when evaluated for behavioral effects in rats or cardiovascular safety effects in dogs. These results support the transition of oxfendazole to First in Human safety studies preliminary to its evaluation in human helminth diseases.<\/jats:p>","DOI":"10.1177\/1091581815569582","type":"journal-article","created":{"date-parts":[[2015,2,26]],"date-time":"2015-02-26T01:58:06Z","timestamp":1424915886000},"page":"129-137","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":23,"title":["Preclinical Studies on the Pharmacokinetics, Safety, and Toxicology of Oxfendazole"],"prefix":"10.1177","volume":"34","author":[{"given":"Ellen E.","family":"Codd","sequence":"first","affiliation":[{"name":"Codd Consulting, LLC, Blue Bell, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna H.","family":"Ng","sequence":"additional","affiliation":[{"name":"SRI International, Biosciences Division, Menlo Park, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"McFarlane","sequence":"additional","affiliation":[{"name":"SRI International, Biosciences Division, Menlo Park, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward S.","family":"Riccio","sequence":"additional","affiliation":[{"name":"SRI International, Biosciences Division, Menlo Park, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupa","family":"Doppalapudi","sequence":"additional","affiliation":[{"name":"SRI International, Biosciences Division, Menlo Park, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon C.","family":"Mirsalis","sequence":"additional","affiliation":[{"name":"SRI International, Biosciences Division, Menlo Park, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. John","family":"Horton","sequence":"additional","affiliation":[{"name":"Tropical Projects, Hitchin, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando E.","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"Veterinary School, San Marcos University, Lima, Peru"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Hugo","family":"Garcia","sequence":"additional","affiliation":[{"name":"Department of Microbiology, School of Sciences and Center for Global Health-Tumbes, School of Sciences, Universidad Peruana Cayetano Heredia, Lima, Peru"},{"name":"Cysticercosis Unit, Instituto Nacional de Ciencias Neurologicas, Lima, Peru"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Gilman","sequence":"additional","affiliation":[{"name":"Johns Hopkins Bloomberg School of Hygiene and Public Health, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2015,2,20]]},"reference":[{"key":"bibr1-1091581815569582","first-page":"1937","volume":"299","author":"Keiser J","year":"2008","journal-title":"Journal of the American Medical Association"},{"key":"bibr2-1091581815569582","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpara.2009.11.001"},{"key":"bibr3-1091581815569582","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14117-7"},{"key":"bibr4-1091581815569582","doi-asserted-by":"publisher","DOI":"10.1016\/j.pt.2004.08.001"},{"key":"bibr5-1091581815569582","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0b013e328359f04a"},{"key":"bibr6-1091581815569582","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetpar.2007.06.028"},{"key":"bibr7-1091581815569582","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1996.54.391"},{"key":"bibr8-1091581815569582","doi-asserted-by":"publisher","DOI":"10.1136\/vr.141.16.420"},{"key":"bibr9-1091581815569582","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1998.59.832"},{"key":"bibr10-1091581815569582","doi-asserted-by":"publisher","DOI":"10.1016\/j.fct.2012.07.023"},{"key":"bibr11-1091581815569582","unstructured":"Oxfendazole, Fenbendazole, Febantel, Summary Report: Committee for Veterinary Medicinal Products, EMEA; 1997."},{"key":"bibr12-1091581815569582","unstructured":"Oxfendazole Summary Report (3): Committee for Veterinary Medicinal Products, EMEA; 1997."},{"key":"bibr13-1091581815569582","unstructured":"Freedom of Information Summary, NADA 140-854 Synanthic-original approval. 1990. Web site. http:\/\/www.fda.gov\/AnimalVeterinary\/Products\/ApprovedAnimalDrugProducts\/FOIADrugSummaries\/ucm049983.html. Accessed January 26, 2015."},{"key":"bibr14-1091581815569582","unstructured":"Albenza (albendazole). 2009. Web site. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/020666s005s006lbl.pdf. Accessed January 25, 2015."},{"key":"bibr15-1091581815569582","unstructured":"Guideline on Safety Pharmacology Studies for Human Pharmaceuticals. 2001. Website. http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm074959.pdf. Accessed January 25, 2015."},{"key":"bibr16-1091581815569582","doi-asserted-by":"publisher","DOI":"10.1016\/S0027-5107(00)00076-2"},{"key":"bibr17-1091581815569582","doi-asserted-by":"publisher","DOI":"10.1016\/S0027-5107(00)00064-6"},{"key":"bibr18-1091581815569582","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1161(83)90010-9"},{"key":"bibr19-1091581815569582","doi-asserted-by":"publisher","DOI":"10.1016\/0027-5107(79)90195-7"},{"key":"bibr20-1091581815569582","doi-asserted-by":"publisher","DOI":"10.1002\/em.10122"},{"key":"bibr21-1091581815569582","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrgentox.2007.02.004"},{"key":"bibr22-1091581815569582","doi-asserted-by":"publisher","DOI":"10.1016\/0165-7992(83)90096-9"},{"key":"bibr23-1091581815569582","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1218(87)90016-4"},{"key":"bibr24-1091581815569582","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4684-0892-8_2"},{"key":"bibr25-1091581815569582","unstructured":"41-4-Oxfendazole. 2003. Web site. ftp:\/\/ftp.fao.org\/ag\/agn\/jecfa\/vetdrug\/41-4-oxfendazole.pdf. Accessed January 25, 2015."},{"key":"bibr26-1091581815569582","doi-asserted-by":"publisher","DOI":"10.1016\/S0001-706X(03)00031-7"},{"key":"bibr27-1091581815569582","doi-asserted-by":"publisher","DOI":"10.1080\/01926230490260655"},{"key":"bibr28-1091581815569582","doi-asserted-by":"publisher","DOI":"10.1017\/S0031182000007290"},{"key":"bibr29-1091581815569582","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrgentox.2006.09.004"},{"key":"bibr30-1091581815569582","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2007.01.002"},{"key":"bibr31-1091581815569582","doi-asserted-by":"publisher","DOI":"10.1051\/rnd:2006007"},{"key":"bibr32-1091581815569582","doi-asserted-by":"publisher","DOI":"10.1002\/em.2860020110"}],"container-title":["International Journal of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1091581815569582","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1091581815569582","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1091581815569582","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:24:41Z","timestamp":1777458281000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1091581815569582"}},"subtitle":["Toward First in Human Studies"],"short-title":[],"issued":{"date-parts":[[2015,2,20]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["10.1177\/1091581815569582"],"URL":"https:\/\/doi.org\/10.1177\/1091581815569582","relation":{},"ISSN":["1091-5818","1092-874X"],"issn-type":[{"value":"1091-5818","type":"print"},{"value":"1092-874X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,20]]}}}